Cargando…

Adverse events after first COVID-19 vaccination in patients with autoimmune diseases

Detalles Bibliográficos
Autores principales:	Boekel, Laura, Kummer, Laura Y, van Dam, Koos P J, Hooijberg, Femke, van Kempen, Zoé, Vogelzang, Erik H, Wieske, Luuk, Eftimov, Filip, van Vollenhoven, Ronald, Kuijpers, Taco W, van Ham, S Marieke, Tas, Sander W, Killestein, Joep, Boers, Maarten, Nurmohamed, Mike T, Rispens, Theo, Wolbink, Gertjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213359/ https://www.ncbi.nlm.nih.gov/pubmed/34179831 http://dx.doi.org/10.1016/S2665-9913(21)00181-8

Ejemplares similares

Perspective of patients with autoimmune diseases on COVID-19 vaccination
por: Boekel, Laura, et al.
Publicado: (2021)

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
por: Boekel, Laura, et al.
Publicado: (2021)

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
por: Boekel, Laura, et al.
Publicado: (2022)

Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population
por: Hooijberg, Femke, et al.
Publicado: (2020)

Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
por: van Kempen, Zoé L.E., et al.
Publicado: (2022)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022)

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study
por: Boekel, Laura, et al.
Publicado: (2022)

Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination
por: van Dam, Koos P. J., et al.
Publicado: (2022)

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
por: van Kempen, Zoé L. E., et al.
Publicado: (2022)

Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273
por: Verstegen, Niels JM, et al.
Publicado: (2022)

Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands
por: Boekel, Laura, et al.
Publicado: (2023)

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases
por: Boekel, Laura, et al.
Publicado: (2022)

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
por: van Kempen, Z.L.E., et al.
Publicado: (2022)

Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated
por: Raadsen, Reinder, et al.
Publicado: (2023)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Spinning straw into gold: description of a disruptive rheumatology research platform inspired by the COVID-19 pandemic
por: Boekel, L., et al.
Publicado: (2021)

Immunogenicity of TNF-Inhibitors
por: Atiqi, Sadaf, et al.
Publicado: (2020)

Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases
por: Wieske, Luuk, et al.
Publicado: (2022)

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
por: Boekel, Laura, et al.
Publicado: (2022)

Infusion-related events during natalizumab: No need for post-infusion monitoring
por: Loonstra, Floor C, et al.
Publicado: (2019)

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
por: Wientjes, Maike H. M., et al.
Publicado: (2021)

Fingerprick blood samples to measure serum natalizumab concentrations
por: Toorop, Alyssa A, et al.
Publicado: (2022)

Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry”
por: van Vollenhoven, Ronald F, et al.
Publicado: (2023)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Optimized Protocols for In-Vitro T-Cell-Dependent and T-Cell-Independent Activation for B-Cell Differentiation Studies Using Limited Cells
por: Marsman, Casper, et al.
Publicado: (2022)

Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients
por: van Kempen, Zoé LE, et al.
Publicado: (2021)

Serum Contactin-1 in CIDP: A Cross-Sectional Study
por: Wieske, Luuk, et al.
Publicado: (2021)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations
por: van Dam, Koos P.J., et al.
Publicado: (2023)

Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity
por: van Dam, Koos P. J., et al.
Publicado: (2023)

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study
por: Wieske, Luuk, et al.
Publicado: (2022)

Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange
por: van Schie, Karin A., et al.
Publicado: (2016)

Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post‐hoc analysis of the immunoglobulin overtreatment in CIDP trial
por: van Veen, Robin, et al.
Publicado: (2022)

COVID-19 in multiple sclerosis: The Dutch experience
por: Loonstra, Floor C, et al.
Publicado: (2020)

Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity
por: van Schie, Karin A, et al.
Publicado: (2015)

Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations
por: Vlot, Mariska C, et al.
Publicado: (2019)

Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials
por: Wieske, Luuk, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lj752jc98010dp8hs46k200u72